OtherArticle
Influence of Erythromycin on the Pharmacokinetics of Ximelagatran May Involve Inhibition of P-glycoprotein-mediated Excretion
Ulf G Eriksson, Hassan Dorani, Johan E Karlsson, Holger Fritsch, Kurt-Jurgen Hoffmann, Lis Ohlsson, Troy C Sarich, Ulrika Wall and Kajs-Marie Schutzer
Drug Metabolism and Disposition February 2, 2006, DOI: https://doi.org/10.1124/dmd.105.008607
Ulf G Eriksson
Hassan Dorani
Johan E Karlsson
Holger Fritsch
Kurt-Jurgen Hoffmann
Lis Ohlsson
Troy C Sarich
Ulrika Wall
This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
OtherArticle
Influence of Erythromycin on the Pharmacokinetics of Ximelagatran May Involve Inhibition of P-glycoprotein-mediated Excretion
Ulf G Eriksson, Hassan Dorani, Johan E Karlsson, Holger Fritsch, Kurt-Jurgen Hoffmann, Lis Ohlsson, Troy C Sarich, Ulrika Wall and Kajs-Marie Schutzer
Drug Metabolism and Disposition February 2, 2006, DOI: https://doi.org/10.1124/dmd.105.008607
OtherArticle
Influence of Erythromycin on the Pharmacokinetics of Ximelagatran May Involve Inhibition of P-glycoprotein-mediated Excretion
Ulf G Eriksson, Hassan Dorani, Johan E Karlsson, Holger Fritsch, Kurt-Jurgen Hoffmann, Lis Ohlsson, Troy C Sarich, Ulrika Wall and Kajs-Marie Schutzer
Drug Metabolism and Disposition February 2, 2006, DOI: https://doi.org/10.1124/dmd.105.008607
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement